MedTrace Logo

Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality

NCT00668707 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 709

Last updated 2021-08-03

Study results available
· View outcomes & findings →

Summary

There is evidence to support the use of melatonin, a natural health product, as an additional treatment aid for cancer patients. This study is designed to see if the daily ingestion of 20 milligrams of melatonin for one year can lower the incidence of developing lung cancer recurrence and/or death. Only patients with a diagnosis of non small cell lung cancer who are eligible for surgical resection can participate in the trial. The study will also be assessing for changes in quality of life, pain, fatigue, anxiety, sleep, and depression amongst the participants.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DIETARY_SUPPLEMENT

melatonin

20 mgs ingested nightly

DIETARY_SUPPLEMENT

placebo

similar to experimental in all ways except for lack of active ingredient

Sponsors & Collaborators

  • The Ottawa Hospital

    collaborator OTHER

  • Lotte & John Hecht Memorial Foundation

    collaborator OTHER

  • Gateway for Cancer Research

    collaborator OTHER

  • The Canadian College of Naturopathic Medicine

    lead OTHER

Principal Investigators

  • Dugald MR Seely, ND, MSc · The Canadian College of Naturopathic Medicine

  • Andrew JE Seely, MD · The Ottawa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2017-03-09
Completion
2017-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00668707 on ClinicalTrials.gov